key: cord-0731439-8lcda5ra authors: Chiarello, M. M.; Cariati, M.; Brisinda, G. title: Assessment of severity of acute pancreatitis in a Sars‐CoV‐2 pandemia date: 2020-07-20 journal: Br J Surg DOI: 10.1002/bjs.11818 sha: fa4343ce37e8834a0416e47ba7cdb52997fc1323 doc_id: 731439 cord_uid: 8lcda5ra HUMAN AND ANIMAL RIGHTS: Every patient has given permission for publication of information from the medical history as long as it is used for medical research purposes. INFORMED CONSENT: Informed consent was obtained from all the individual participants of the study. both due to a direct damage of the pancreas to ACE2 receptors, or secondary to locoregional vasculitis and thrombosis. AP with concomitant COVID-19 is more likely to have poorer outcomes secondary to a double pulmonary insult. In severe AP lung involvement is common, and it can progress to full blown acute respiratory distress syndrome (ARDS). At present, it can be difficult to stratify the severity of symptoms and the degree of lung involvement. A COVID-19 pneumonia can worsen lung injury and ARDS due to AP. In COVID-19 pandemic times, CT-scan should be routinely extended to chest 2 . An early chest CT-scan allows to differentiate a lung involvement secondary to viral infection from ARDS caused by AP. In COVID-19 pneumonia a 'ground glass' finding is present, as pleural effusion and alveolar involvement are later findings. In COVID-19 infection there are segmentary micro-embolism, that are not present in ARDS. The value of goal-directed therapy in patients with AP remains unknown. A study demonstrated tocilizumab, as a marketed drug commonly used for immune-mediated diseases, was safe and effective for the treatment of experimental severe AP and associate lung injury 6 . These findings provide experimental evidences for potential clinical application of tocilizumab in severe AP and associated complications. Management of patients with severe AP is complex and is optimally provided by a multidisciplinary team. Recently, by means of a mnemonic 'PANCREAS', eight important steps in the management of severe AP are highlighted. In the current scenario, it is of paramount importance to consider COVID-19 symptoms, as an early therapy against the virus should be started together with the treatment of severe AP. M. M. Chiarello 1 , M. Cariati 1 and G. Brisinda 1,2 COVID-19 pandemic: perspectives on an unfolding crisis Clinical Characteristics of Coronavirus Disease 2019 in China Gastrointestinal symptoms associated with severity of coronavirus disease 2019 (COVID-19): a pooled analysis COVID-19 and the gastrointestinal tract: more than meets the eye Endothelial cell infection and endotheliitis in COVID-19 Effects of Tocilizumab on Experimental Severe Acute Pancreatitis and Associated Acute Lung Injury